Skip to main content

Table 2 17AAG inhibits the development of DBM2 pulmonary lesions.

From: A highly invasive human glioblastoma pre-clinical model for testing therapeutics

     Lung grade
Group 17AAG dose (mg/kg-d) Body weight (g) Lung weight (g) + ++ +++
1 (n = 8) Vehicle only 17.79 ± 1.88 0.477 ± 0.19 2 (25%) 3 (37.5%) 3 (37.5%)
2 (n = 10) 20 19.88 ± 1.68* 0.412 ± 0.17 3 (30%) 2 (20%) 5 (50%)
3 (n = 10§) 60 20.17 ± 0.89* 0.276 ± 0.11* 8 (80%) 2 (20%) 0
  1. *Compared with group 1; Student's t test was used (p < 0.05)
  2. §Compared with group 1; Chi-square was used for statistical analysis P < 0.05.
  3. For drug testing in the lung metastasis model, 28 nude mice (6-week-old females) were divided into three groups: a control group (n = 8), and 17AAG groups treated with either 20 mg/kg (n = 10) or 60 mg/kg (n = 10). Each mouse received a single intravenous tail vein injection of 106 DBM2 cells in 100 μl PBS. Treatment started the second day after the cells were injected and continued for 8 weeks, by which time most of the control mice were moribund. At necropsy, lungs were harvested and scored; body weight and lung weight of each mouse were also recorded.